Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

Fig. 5

In vivo anti-tumor activity by 19305DP-TCR or CD8SP-TCR-transduced T cells. A375 (1 × 106 cells) was subcutaneously inoculated in NSG mice at day 0. At day 11, 2.5 × 105 TCR-transduced T cells were intravenously transferred. Tumor volume was calculated from tumor diameter measured every 2–3 days. a Tumor growth in mice that received whole PBMC-expressing 19305DP-TCR (n = 11), CD8SP-TCR (n = 11) or NY-ESO-1-specific DR*01-restricted control-TCR-transduced T cells (n = 11) are shown. Tumor alone group received no T cells or IL-2 (n = 8). b Survival of mice in (a) is plotted. c Tumor growth in mice that received isolated CD8+ or CD4+ T cells expressing 19305DP-TCR, CD8SP-TCR or control-TCR is shown (n = 8 per group). d Survival of mice in (c) is shown. Mice were considered to reach endpoint when tumor volume exceeded 2000 mm3. *p < 0.05, ****p < 0.0001 compared with CD8SP

Back to article page